HIND Stock Rallies 70% Pre-Market Today – Find Out Why

Vyome Holdings, Inc. (HIND) announced on Wednesday that its VT-1908 eyedrops has been shown to significantly reduce uveitis scores in preclinical models. Shares of the company rallied 18% on Wednesday morning at the time of writing. 

Uveitis is the inflammation of a part of the eye and is implicated in approximately 30,000 new cases of legal blindness annually in the United States alone, according to Vyome.  

In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, and the efficacy of the drug was found to be similar to a clinically used steroid, the company stated.

On Stocktwits, retail sentiment around HIND stock jumped from ‘neutral’ to ‘extremely bullish territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels. Shares of the company traded as high as 70% in the pre-market session. 

According to Vyome, steroids are the first line of treatment for uveitis, but many patients do not respond to them, and they also cause major complications. “There is a huge unmet need for a topically administered drug to replace steroid use in the eye. Vyome is developing VT-1908 to address this major unmet need,” the company said while adding that the broader addressable global market to treat inflammation in the eye is expected to exceed $20 billion by 2030.

“We are excited with the preclinical efficacy signals. We expect to initiate Phase 1/2 clinical trial in the second half of 2026,” CEO Venkat Nelabhotla said. While the company will initially target uveitis, the long-term goal is to replace steroids to treat ocular inflammation, he said.

HIND stock is down by 98% this year and by about 99% over the past 12 months. 

Read also: Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on